At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
MK-0941 +2 moredrug
Likely dose
MK-0941 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin
In Brief
A Phase 2 clinical trial evaluating MK-0941, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 68 participants.
Detailed Summary
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionMay 2010
TodayJul 2026
First PostedJan 19, 2009
Enrollment StartJan 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.5 years ago
Interventions
MK-0941drug
MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
Placebodrug
Placebo tablets, taken 3 times daily.
Insulindrug
Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.